Investing in Supernus Pharmaceuticals Inc. (SUPN) Is Getting More Attractive

0
8

In a filing, Supernus Pharmaceuticals Inc. revealed its Sr. V.P., Regulatory Affairs Martin Tami Tillotson unloaded Company’s shares for reported $0.18 million on Aug 22. In the deal valued at $35.98 per share,5,000 shares were sold. As a result of this transaction, Martin Tami Tillotson now holds 87,220 shares worth roughly $ 3.03 million.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Then, Khattar Jack A. sold 14,690 shares, generating $499,651 in total proceeds. Upon selling the shares at $34.01, the President, CEO now owns 775,559 shares.

Before that, Khattar Jack A. sold 17,302 shares. Supernus Pharmaceuticals Inc. shares valued at $588,752 were divested by the President, CEO at a price of $34.03 per share. As a result of the transaction, Khattar Jack A. now holds 759,901 shares, worth roughly $26.38 million.

PT values the company’s stock at a premium of 21.09 to its Monday closing price. A number of analysts have revised their coverage, including Jefferies’s analysts, who increased its forecast for the stock in mid April from “a Hold” to “a Buy”. Piper Sandler also remained covering SUPN and has increased its forecast on June 16, 2020 with a “an Overweight” recommendation from previously “Neutral” rating.

Price Performance Review of SUPN

On Monday, Supernus Pharmaceuticals Inc. [NASDAQ:SUPN] saw its stock jump 2.12% to $34.72. On the same session, the stock had its day’s lowest price of $33.70, but rose to a high of $34.80. Over the last five days, the stock has gained 1.31%. Supernus Pharmaceuticals Inc. shares have risen nearly 19.07% since the year began. Nevertheless, the stocks have risen 7.83% over the past one year. While a 52-week high of $36.08 was reached on 08/22/22, a 52-week low of $24.95 was recorded on 05/11/22. SMA at 50 days reached $33.81, while 200 days put it at $31.09. A total of 0.51 million shares were traded, compared to the trading of 0.34 million shares in the previous session.

Levels Of Support And Resistance For SUPN Stock

The 24-hour chart illustrates a support level at 34.01, which if violated will result in even more drops to 33.31. On the upside, there is a resistance level at 35.11. A further resistance level may holdings at 35.51. The Relative Strength Index (RSI) on the 14-day chart is 57.38, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.23, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 15.49%. Stochastics %K at 73.90% indicates the stock is a holding.

How much short interest is there in Supernus Pharmaceuticals Inc.?

A steep rise in short interest was recorded in Supernus Pharmaceuticals Inc. stocks on Jul 14, 2022, growing by 0.12 million shares to a total of 5.63 million shares. Yahoo Finance data shows the prior-month short interest on Jun 14, 2022 was 5.51 million shares. There was a rise of 2.13%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 15.04% of the overall stock float, the days-to-cover ratio (short ratio) rose to 17.95.

Supernus Pharmaceuticals Inc. [SUPN] – Who Are The Largest Shareholders?

In filings from BlackRock Fund Advisors, it is revealed that the company now owns 7,764,641 shares, or roughly 14.52% of the outstanding SUPN shares. In other words, the investor’s shares have fallen by -4,032 from its previous 13-F filing of 7768673.0. Additionally, The Vanguard Group, Inc. increased 1.47% of its stake after which the total value it holdings stand at $187,431,546, while Armistice Capital LLC added 52.00% of its stake to hold $159.5 million in the firm. Over the last quarter, Macquarie Investment Management B purchased 165,876 shares of Supernus Pharmaceuticals Inc., while Dimensional Fund Advisors LP bought 17,805 shares. At present, SSgA Funds Management, Inc. is holding 1,978,181 shares valued at $66.96 million. GW&K Investment Management LLC owned 1,909,849 shares of the company at the time of its most recent 13F filing, worth $64.65 million.

However, 3 analysts have rated SUPN stock as an Overweight in their predictions for 2022.

LEAVE A REPLY

Please enter your comment!
Please enter your name here